Global Atomic Re-establishes At-The-Market Equity Program

Global Atomic (GLO.TO) re-established an At-The-Market equity program (ATM) which allows it to issue, at its discretion, its common shares having an offering price of up to C$50 million to the public from time to time during the period ended April 30, 2028, it said overnight Thursday.

The ATM replaces its previous ATM that expired Dec. 21, 2025, under which it issued 13.4-million common shares to raise $13.48 million at $1.00 apiece over a two-year period.

The company intends to use proceeds from the ATM for the continued development of its Dasa Project in the Republic of Niger and for general corporate needs.

Shares of the company closed down 5% to $0.76 on Thursday on the Toronto Stock Exchange.

Golden Minerals Launches Equity Financing While Subsidiaries Sell Out of Minera William

Two wholly-owned subsidiaries of Golden Minerals (AUMN.TO) entered into a definitive agreement to sell their shares in Minera William for US$1.2 million to Streamline Metals Capital and Horizon Silver Resources, the company said overnight Thursday.Minera William principally held tax losses and a royalty interest in the San Diego project in Mexico, Golden Minerals noted.Separately, Golden Minerals entered into a private placement equity financing arrangement for $856,463 in gross proceeds.Under the subscription agreement, Streamline agreed to purchase 3,740,000 common shares of Golden Minerals, priced at $0.229 per share. Upon completion around May 20, Streamline will hold approximately 19.9% of issued and outstanding shares of Golden Minerals.Golden Minerals plans to use the proceeds from the sale and financing to advance the Sand Canyon project in Nevada and Sarita/Desierto project in Argentina.The company will also use the funds to evaluate new project opportunities in Bolivia, and for general working capital and corporate purposes.Shares in AUMN were slightly lower in Canada yesterday.

$AUMN.TO

HLS Therapeutics Q1 Net Loss Narrows on Lower Costs, Higher Revenue

HLS Therapeutics (HLS.TO) first-quarter net loss narrowed on lower costs and higher revenue, the company said on Friday.Net loss contracted to US$2.3 million, or US$0.07 per share, from a net loss of US$4.4 million, or US$0.14 per share, in the prior year period. The improvement was due to lower finance and related costs and higher revenue. Analysts polled by FactSet had forecast a loss of US$0.12 per share.Revenue rose 2% to US$12.9 million, up 2% year-over-year, meeting the US$12.9 million forecast. HLS said Vascepa net sales grew 15% to US$4.8 million, the strongest quarterly growth since the second quarter of last year.The company launched its LDL-cholesterol lowering drug Nilemdo in April, which it reported is off to "a positive start" with weekly sales running ahead of forecast.HLS reaffirmed its 2026 consolidated revenue guidance of US$56 million to US$60 million, representing mid-single-digit percentage growth."Q1 results were in line with our expectations and consistent with our annual guidance," said chief executive Craig Millian. "The increase in revenue was driven by Vascepa, which had its strongest quarterly growth since mid-2025 and is a validation of the changes we made to strengthen the cardiovascular sales team last year."HLS shares closed down $0.02, to $4.67, on Thursday on the Toronto Stock Exchange.

$HLS.TO

Global Atomic Re-establishes At-The-Market Equity Program

Related Articles

Golden Minerals Launches Equity Financing While Subsidiaries Sell Out of Minera William

HLS Therapeutics Q1 Net Loss Narrows on Lower Costs, Higher Revenue

Transat Providing Update On "Volatility" Of Aviation Fuel Prices